MicroRNA delivery strategies to the lung in a model of pulmonary hypertension

Deng, L., Baker, A. H. and Bradshaw, A. C. (2017) MicroRNA delivery strategies to the lung in a model of pulmonary hypertension. In: Ishikawa, K. (ed.) Cardiac Gene Therapy: Methods and Protocols. Series: Methods in molecular biology (1521). Humana Press: New York, NY, pp. 325-338. ISBN 9781493965861 (doi: 10.1007/978-1-4939-6588-5_23)

Full text not currently available from Enlighten.

Publisher's URL: http://www.springer.com/gb/book/9781493965861


Pulmonary arterial hypertension (PAH) is characterized by enhanced proliferation of pulmonary artery smooth muscle cells and endothelial cells associated with obliteration of small pulmonary arterioles and formation of plexiform lesions. To date, no curative treatments have been identified for pulmonary arterial hypertension. There are various therapeutic options, including conventional medical therapies and oral, subcutaneous, intravenous, and inhalation delivery. We have previously shown that miR-143/145 knockout can prevent the development of chronic hypoxia-induced pulmonary hypertension (PH) in mice. Here, we use chronic hypoxia-induced PH as a disease model to evaluate miR-143/145 inhibition after delivery of antimiRNAs via the subcutaneous or intranasal routes. We use qRT-PCR and immunofluorescence to confirm that both delivery strategies efficiently inhibit miR-143/145 in lung tissue from mice with chronic hypoxia-induced PH.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Bradshaw, Dr Angela and Baker, Professor Andrew
Authors: Deng, L., Baker, A. H., and Bradshaw, A. C.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Publisher:Humana Press
Published Online:02 December 2016

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
597901Development of MiR145 Antagonism as a novel Therapeutic strategy for Application to the treatment of pulmonary arterial hypertension.Andrew BakerBritish Heart Foundation (BHF)SP/12/9/29593RI CARDIOVASCULAR & MEDICAL SCIENCES